Dual treatment with lopinavir–ritonavir plus lamivudine versus triple treatment with lopinavir–ritonavir plus lamivudine or emtricitabine and a second nucleos(t)ide reverse transcriptase inhibitor for maintenance of HIV-1 viral suppression (OLE): a randomised, open-label, non-inferiority trialJosé Ramón Arribas, José M. Gatell, Josep Mallolas et al.|The Lancet Infectious Diseases|2015Cited by 143
Costs and cost-efficacy analysis of the 2016 GESIDA/Spanish AIDS National Plan recommended guidelines for initial antiretroviral therapy in HIV-infected adultsAntonio Rivero, Josep M. Gatell, José A. Pérez‐Molina et al.|Enfermedades Infecciosas y Microbiología Clínica|2016Cited by 22